

00000272959

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS

03 AUG 12 PM 1:45

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Ricchetti Incorporated</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>1001 G Street NW Suite 700 East</u>			
3. Principal Place of Business (if different from line 2) City: <u>Washington</u> State/Zip (or Country) <u>DC 20001</u>			
4. Contact Name <u>James Heimbsch</u>	Telephone <u>(202) 879-9367</u>	E-mail (optional)	5. Senate ID <u>62778</u>
7. Client Name <input type="checkbox"/> Self <u>Novartis</u>			6. House ID <u>35393</u>

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobb

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>60,000⁰⁰</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for descriptive</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA de</p> <p><input type="checkbox"/> Method B. Reporting amounts under section Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section Internal Revenue Code</p>
---	---

Signature _____

Printed Name and Title James T. Heimbsch Vice President

LD-2 (REV. 6/98)

Printed Name and Title James T. Heimbach Vice President

Form LD-2 (Rev. 6/98)

01:00:00
2961

Registrant Name Ricchetti Inc. Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues
Generic drug availability / Patent Protection
S.54 - Greater Access to Affordable Pharmaceuticals Act

Issues pertaining to generic pharmaceuticals and the impact on pharmaceutical companies.

17. House(s) of Congress and Federal agencies contacted Check if None

US Senate
US House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Steve Ricchetti</u>	
<u>Jeff Ricchetti</u>	
<u>Lisa Kountoupas</u>	
<u>James Heimbruch</u>	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis is owned by Novartis AG, Basel Switzerland

Signature [Signature] Date 8/7/03

Printed Name and Title James T. Heimbech Vice President

Form LD-2 (Rev. 6/98)

Registrant Name Ricchetti Inc. Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Reimportation of Prescription Drugs
HR 2427 Pharmaceutical Market Access Act of 2023

All issues pertaining to regulations for the reimportation of drugs into the United States.

17. House(s) of Congress and Federal agencies contacted Check if None

US House

US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Steve Ricchetti	
Jeff Ricchetti	
Lisa Kounoupes	
James Heimbach	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis Corporation is owned by Novartis AG Basel Switzerland

Signature [Signature] Date 8/7/20

Printed Name and Title James T. Heimbech Vice President ' '

Form LD-2 (Rev.6/98)

01000000296

Registrant Name Ricchetti Inc. Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicaid Reform

Issues pertaining to the President's proposed reform of Medicaid.

17. House(s) of Congress and Federal agencies contacted

Check if None

US House
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Steve Ricchetti</u>
<u>Jeff Ricchetti</u>
<u>Lisa Kountoupes</u>
<u>James Heimlich</u>
.....
.....
.....
.....

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Novartis Corporation is owned by Novartis AG, Basel S

Signature [Signature] Date 8/7/08

Printed Name and Title James T. Heimbech Vice President

Form LD-2 (Rev. 6/98)

Printed Name and Title James T. Heimbach Vice President

Form LD-2 (Rev. 6/98)

1